NASDAQ:APLT Applied Therapeutics (APLT) Stock Price, News & Analysis $0.39 -0.01 (-2.25%) Closing price 04:00 PM EasternExtended Trading$0.40 +0.01 (+2.31%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Applied Therapeutics Stock (NASDAQ:APLT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Applied Therapeutics alerts:Sign Up Key Stats Today's Range$0.38▼$0.4150-Day Range$0.30▼$0.6052-Week Range$0.30▼$10.62Volume1.21 million shsAverage Volume3.37 million shsMarket Capitalization$54.66 millionP/E RatioN/ADividend YieldN/APrice Target$6.10Consensus RatingModerate Buy Company OverviewApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Read More… Applied Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreAPLT MarketRank™: Applied Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 193rd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingApplied Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageApplied Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Applied Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Applied Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Applied Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Applied Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Applied Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.61% of the float of Applied Therapeutics has been sold short.Short Interest Ratio / Days to CoverApplied Therapeutics has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Applied Therapeutics has recently increased by 25.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApplied Therapeutics does not currently pay a dividend.Dividend GrowthApplied Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.88 Percentage of Shares Shorted18.61% of the float of Applied Therapeutics has been sold short.Short Interest Ratio / Days to CoverApplied Therapeutics has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Applied Therapeutics has recently increased by 25.02%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment0.99 News SentimentApplied Therapeutics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Applied Therapeutics this week, compared to 8 articles on an average week.Search Interest5 people have searched for APLT on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows3 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Applied Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.60% of the stock of Applied Therapeutics is held by insiders.Percentage Held by Institutions98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Applied Therapeutics' insider trading history. Receive APLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APLT Stock News HeadlinesApplied announces INSPIRE Phase 2/3 trial primary endpoint not significantMay 18, 2025 | msn.comApplied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual MeetingMay 18, 2025 | globenewswire.com“Biggest Social Security Change Ever”The Financial Times called this new Trump initiative "a big pot of money for the American people." And The Motley Fool said that it could "pave the way for the biggest Social Security change ever."June 10, 2025 | InvestorPlace (Ad)Applied Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comApplied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual MeetingMay 9, 2025 | globenewswire.comNET Power Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 17, 2025 Deadline to file Lead Plaintiff MotionApril 22, 2025 | globenewswire.comWilliam Blair Sticks to Its Hold Rating for Applied Therapeutics (APLT)April 15, 2025 | markets.businessinsider.comApplied Therapeutics (APLT) Gets a Hold from RBC CapitalApril 15, 2025 | markets.businessinsider.comSee More Headlines APLT Stock Analysis - Frequently Asked Questions How have APLT shares performed this year? Applied Therapeutics' stock was trading at $0.8562 at the beginning of the year. Since then, APLT shares have decreased by 54.9% and is now trading at $0.3861. View the best growth stocks for 2025 here. How were Applied Therapeutics' earnings last quarter? Applied Therapeutics, Inc. (NASDAQ:APLT) released its earnings results on Monday, April, 14th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.06. The business had revenue of $0 million for the quarter, compared to the consensus estimate of $0.61 million. When did Applied Therapeutics IPO? Applied Therapeutics (APLT) raised $60 million in an IPO on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager. Who are Applied Therapeutics' major shareholders? Top institutional investors of Applied Therapeutics include Propel Bio Management LLC (7.97%), T. Rowe Price Investment Management Inc. (7.33%), Alyeska Investment Group L.P. (2.19%) and Charles Schwab Investment Management Inc. (0.45%). Insiders that own company stock include Real Estate Equitie Alexandria, Shoshana Shendelman, Riccardo Perfetti, Leslie D Funtleyder and Stacy J Kanter. View institutional ownership trends. How do I buy shares of Applied Therapeutics? Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Applied Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW). Company Calendar Last Earnings4/14/2025Today6/10/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APLT CIK1697532 Webwww.appliedtherapeutics.com Phone(212) 220-9226FaxN/AEmployees30Year Founded2017Price Target and Rating Average Stock Price Target$6.10 High Stock Price Target$14.00 Low Stock Price Target$1.50 Potential Upside/Downside+1,479.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$119.76 million Net MarginsN/A Pretax MarginN/A Return on Equity-260.75% Return on Assets-76.04% Debt Debt-to-Equity RatioN/A Current Ratio1.06 Quick Ratio1.06 Sales & Book Value Annual Sales$265 thousand Price / Sales206.27 Cash FlowN/A Price / Cash FlowN/A Book Value($0.20) per share Price / Book-1.93Miscellaneous Outstanding Shares141,576,000Free Float106,349,000Market Cap$54.66 million OptionableOptionable Beta1.86 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:APLT) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Applied Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.